Impact of Obesity on Cardiovascular Disease

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 3, 2008, Pages 663-684

  Zalesin, Kerstyn C ^a   Franklin, Barry A ^a   Miller, Wendy M ^a   Peterson, Eric D ^b   McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SLEEP APNEA SYNDROME;

ANIMALS; ATRIAL FIBRILLATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; HEART FAILURE; HUMANS; HYPERTENSION; OBESITY;

EID: 50449105392     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.06.004     Document Type: Review

References (123)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among U.S. adults, 1999-2000. JAMA 288 (2002) 1723-1727
2. Popkin B.M. The nutrition transition and its health implications in lower income countries. Public Health Nutr 1 (1998) 5-21
3. Willett W.C., Manson J.E., Stampfer M.J., et al. Weight, weight change and coronary heart disease in women: risk within the "normal" weight range. JAMA 273 6 (1995) 461-465
4. Allison D.B., Fontaine K.R., Manson J.E., et al. Annual deaths attributable to obesity in the United States. JAMA 282 (1999) 1530-1538
5. Fontaine K.R., Redden D.T., Wang C., et al. Years lost of life due to obesity. JAMA 289 (2003) 187-193
6. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Eng J Med 352 (2005) 1138-1145
7. Ogden C.L., Flegal K.M., Carroll M.D., et al. Prevalence and trends in overweight among U.S. children and adolescents, 1999-2000. JAMA 288 (2002) 1728-1732
8. U.S. Department of Health and Human Services. The Surgeon General's call to action to prevent and decrease overweight and obesity (2001), U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville (MD) Available from: U.S. GPO, Washington
9. Must A., Jacques P.F., Dallal G.E., et al. Long-term morbidity and mortality of overweight adolescents: a follow-up of the Harvard Growth Study of 1922 to 1935. N Eng J Med 327 (1992) 1350-1355
10. Freedman D.S., Dietz W.H., Srinivasan S.R., et al. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 103 (1999) 1175-1182
11. Berenson G.S., Srinivasan S.R., Bao W., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N End J Med 338 (1998) 1650-1656
12. Pouliot M.C., Despres J.P., Lemieux S., et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J cardiol 73 (1994) 460-468
13. Heart disease and stroke statistics-2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
14. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of US adults. N Eng J Med 341 (1999) 1097-1105
15. Yusuf S., Hawken S., Ōunpuu S., et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 366 (2005) 1640-1649
16. De Koning L., Merchant A.T., Pogue J., et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur heart J 28 7 (2007) 850-856
17. Schulte H., Cullen P., and Assmann G. Obesity, mortality and cardiovascular disease in the Munster Heart Study (PROCAM). Atherosclerosis 144 1 (1999) 199-209
18. Bogers R.P., Bemelmans W.J., Hoogenveen R.T., et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels. Arch Intern Med 167 16 (2007) 1720-1728
19. Hubert H.B., Feinleib M., McNamara P.M., et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67 5 (1983) 968-977
20. Eisenstein E., Shaw L., Nelson C., et al. Obesity and long-term clinical and economic outcomes in coronary artery disease patients. Obes Res 10 (2002) 83-91
21. Eckel R.H. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 96 9 (1997) 3248-3250
22. Levy D., and Wilson P.W. Atherosclerotic cardiovascular disease: an epidemiologic perspective. In: Topol E.J. (Ed). Text of cardiovascular medicine (1998), Lippincott-Raven, Philadelphia 13-30
23. Chen Y.T., Vaccarino V., Williams C.S., et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 106 (1999) 605-612
24. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161 (2001) 996-1002
25. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 5 (2002) 305-313
26. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 321 (2001) 225-236
27. Kasper E.K., Hruban R.H., and Baughman K.L. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 70 (1992) 921-924
28. Ku C.S., Lin S.L., Wang D.J., et al. Left ventricular filling in young normotensive obese adults. Am J Cardiol 73 (1994) 613-615
29. Masserli F.H. Cardiomyopathy of obesity-a not so Victorian disease. N Engl J Med 314 (1986) 378-380
30. Wong C.Y., O'Moore-Sullican T., Fang Z.Y., et al. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol 96 (2005) 1686-1691
31. Malavazos A.E., Ermetici F., Coman C., et al. Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 121 1 (2007) 132-134
32. Smith H.L., and Willius F.A. Adiposity of the heart. Arch Intern Med 52 (1933) 811-831
33. Iacobellis G., Corradi D., and Sharma A.M. Epicardial adipose tissue: anatomic, biomolecular and clinical relationship with the heart. Nat clin pract Cardiovasc Med 2 (2005) 536-543
34. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144 (2003) 5159-5165
35. Lee Y., Hirose H., Ohneda M., et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 91 (1994) 10878-10882
36. McGavrock J.M., Victor R.G., Unger R.H., et al. Adiposity of the heart, revisited. Ann Intern Med 144 (2006) 517-524
37. Ezekowitz M.D. Atrial fibrillation: the epidemic of the new millennium. Ann Intern Med 131 (1999) 537-538
38. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implication of rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001) 2370-2375
39. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292 (2004) 2471-2477
40. Pritchett A.M., Jacobsen S.J., Mahoney D.W., et al. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 41 (2003) 1036-1043
41. Frost L., Juul Hune L., and Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health study. Am J Med 118 (2005) 489-495
42. Gami A.S., Caples S.M., and Somers V.K. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am 32 (2003) 869-894
43. Bozkurt B., and Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 150 (2005) 1233-1239
44. Curtis J.P., Selter J.G., Wang Y., et al. The obesity paradox. Arch Intern Med 165 (2005) 55-61
45. Lopez-Jimenez F., Jacobson S.J., Reeder G.S., et al. Prevalence and secular trends of excess body weight and impact on outcomes after myocardial infarction in the community. Chest 125 4 (2004) 1205-1212
46. Uretsky S., Messerli F.H., Bangalore S., et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 120 (2007) 863-870
47. Gruberg L., Mercado N., Milo S., et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: the obesity paradox II?. Am J Cardiol 95 (2005) 439-444
48. Nikolsky E., Stone G.W., Grines C.L., et al. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J 151 (2006) 168-175
49. Curtis J.P., Selter J.G., Wang Y., et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165 1 (2005) 55-61
50. Romero-Corral A., Montori V.M., Somers V.K., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368 (2006) 666-678
51. Kaplan R.C., Heckbert S.R., Furburg C.D., et al. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 55 (2002) 654-664
52. Grum H.S., Whitlow P.L., and Kip K.E. The impact of body mass index on short-term and long-term outcomes inpatients undergoing coronary revascularization. (BARI). J Am Coll Cardiol 39 (2002) 834-840
53. Lissin L.W., Gauri A.J., Froelicher V.F., et al. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 8 (2002) 206-215
54. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
55. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
56. Roper N.A., Bilous R.W., Kelly W.F., et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 332 (2001) 1389-1393
57. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
58. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
59. National Cholesterol Education Program, Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 285 19 (2001) 2486-2498
60. Natham D.M., Cleary P.A., Backlund J.Y., et al. for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
61. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 348 (2003) 383-393
62. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544
63. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerence. N Engl J Med 346 (2002) 393-403
64. Knowler W.C., Barnett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention. N Eng J Med 346 (2002) 393-403
65. Garrison R.J., Kannel W.B., Stokes M.E., et al. Incidence and precursors of hypertension in young adults: the Framingham offspring study. Prev Med 16 (1987) 235-251
66. El-Atat F., Aneja A., Mcfarlane S., et al. Obesity and hypertension. Endocinol Metab Clin North Am 32 (2003) 832-854
67. Engeli S., and Sharma A.M. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 17 (2002) 355-359
68. Toto R.D. Treatment of hypertension in chronic kidney disease. Semin Nephrol 25 (2005) 435-439
69. Lewington S., Clarke R., Qizilbash N., et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
70. Stamler J., Stamler R., and Neaton J.D. Blood pressure systolic and diastolic and cardiovascular risks. US population data. Arch Intern Med 153 (1993) 598-615
71. Frohlich E.D., Epstein C., Chobanian A.V., et al. The heart in hypertension. N Engl J Med 327 (1992) 998-1008
72. Hall J.E., Hildebrandt D.A., and Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 14 (2001) 103S-115S
73. He J., and Whelton P.K. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 138 (1999) 211-219
74. Chobanian A.V., Bakris G.L., Black H.R., et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
75. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
76. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 342 3 (2000) 145-153
77. Pedersen T.R. Six-year follow-up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. N Eng J Med 313 (1985) 1055-1058
78. Tuck M.L. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension 19 (1992) 167-177
79. Genest J.J., Martin-Munley S.S., McNamara J.R., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85 6 (1992) 2025-2033
80. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 Suppl (1998) 7B-12B
81. Garber A.M., and Alvins A.L. Triglyceride concentration and coronary heart disease. Not yet proved of value as a screening test. BMJ 309 6946 (1994) 2-3
82. Austin M.A., King M.C., Vranizan K.M., et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 2 (1990) 495-506
83. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93 9 (1996) 1647-1650
84. Griffin J.H., Fernandez J.A., and Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 86 1 (2001) 386-394
85. Grundy S.M., Cleeman J.I., Mez C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
86. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
87. Robins S.J., Rubins H.B., Faas F.H., et al., for the VA-HIT Study Group. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
88. Keech A., Simes R.J., Barter P., et al. for the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) randomized controlled trial. Lancet 366 (2005) 1849-1861
89. Goff D.C., Gerstein H.C., Ginsberg H.N., et al. Prevention in cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 Suppl (2007) 4i-20i
90. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutritional Examination Survey. JAMA 287 3 (2002) 356-359
91. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
92. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
93. Hunt K.J., Resendez R.G., Williams K., et al. National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
94. Forseca V.A. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes. Am J Med 120 (2007) S18-S25
95. Després J.-P., Lamrche B., Mauriége P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
96. Olefsky J.M., Farqunar J.W., and Reaven G.M. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 57 (1974) 551-560
97. Miller W.M., Nori Janosz K.E., Yanez J., et al. Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther 3 4 (2005) 743-759
98. Juonala M., Viikari J.S., Laitinen T., et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns study. Circulation 110 (2004) 2918-2923
99. Eschwege E., Richard J.L., Thibult N., et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl 15 (1985) 41s-46s
100. Foneseca V., Desouza C., Asnani S., et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
101. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimipiride on carotid-media thickness in type 2 diabetes. JAMA 296 (2006) 2572-2581
102. Tenenbaum A., and Motro M Fisman E.Z. Dual and panperoxisome proliferators-activated receptors (PPAR) co-agonism: the benzafibrate lessons. Cardiovasc Diabetol 4 (2005) 14-19
103. Keane W.F., and Eknoyan G. Proteinuria, Albuminuria, Risk Assessment, Detection, Elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
104. Yudkin J.S. Hyperinsulinemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med 28 (1996) 433-438
105. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 47 (1998) 793-800
106. deZeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
107. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 21 (2003) 1761-1769
108. Lefebre A.M., Laville M., Vega N., et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47 (1998) 98-103
109. Rosito G.A., D'Agostino R.B., Massaro J., et al. Association between obesity and a prothrombotic state: the Framingham offspring study. Thromb Haemost 91 (2004) 683-689
110. Kohler H.P., and Grant P.J. Plasminogen-activating inhibitor type 1 and CAD. N Engl J Med 342 (2000) 1792-1801
111. Ridker P.M., Cushman M., Stamfer M.J., et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 336 (1997) 973-979
112. Pearson T.A., Mensah G.A., Alexander R.W., et al. American heart association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers and health policy makers from the American heart association expert panel on population and prevention science. Circulation 107 (2003) 645-651
113. Ridker P.M., and for the JUPITTER Study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
114. McConnell J.P., and Hoefner D.M. Lipoprotein-associated phospholipase A2. Clin Lab Med 26 3 (2006) 679-697
115. Grunstein K., Wilcox I., Yang T.-S., et al. Snoring and sleep apnea in men: association with central obesity and hypertension. Int J Obes 17 (1993) 533-540
116. Malhotra A., and White D.P. Obstructive sleep apnea. Lancet 360 9328 (2002) 237-245
117. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Eng J Med 328 17 (1993) 1230-1235
118. Blankfield R.P., Hudgel D.W., Tapolyai A.A., et al. Bilateral leg edema, obesity pulmonary hypertension and obstructive sleep apnea. Arch Intern Med 160 (2000) 2357-2362
119. Young T., Peppard P., Palta M., et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 157 (1997) 1746-1752
120. Gami A.S., Pressman G., Caples S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110 (2004) 364-367
121. Shahar E., Whitney C.W., Redline S., et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health study. Am J Respir Crit Care Med 163 (2001) 19-25
122. Peker Y., Kraiczi H., Hedner J., et al. An independent association between obstructive sleep apnea and coronary artery disease. Eur Respir J 14 1 (1999) 179-184
123. Dyken M.E., Somers V.K., Yamanda T., et al. Investigating the relationship between stroke and obstructive sleep apnea. Stroke 27 (1996) 401-407